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AbstrACt
Objectives Effects of the UK Department of Health’s 
national Enhanced Recovery After Surgery (ERAS) 
Programme on outcomes after primary hip replacement.
Design Natural experimental study using interrupted time 
series to assess the changes in trends before, during and 
after ERAS implementation (April 2009 to March 2011).
setting Surgeries in the UK National Joint Registry were 
linked with Hospital Episode Statistics containing inpatient 
episodes from National Health Service trusts in England 
and patient reported outcome measures.
Participants Patients aged ≥18 years from 2008 to 2016.
Main outcome measures Regression coefficients of 
monthly means of length of hospital stay, bed day cost, 
change in Oxford Hip Scores (OHS) 6 months post- surgery, 
complications 6 months post- surgery and revision rates 5 
years post- surgery.
results 438 921 primary hip replacements were 
identified. Hospital stays shortened from 5.6 days in 
April 2008 to 3.6 in December 2016. There were also 
improvements in bed day costs (£7573 in April 2008 
to £5239 in December 2016), positive change in self- 
reported OHS from baseline to 6 months post- surgery 
(17.7 points in April 2008 to 22.9 points in December 
2016), complication rates (4.1% in April 2008 to 1.7% 
March 2016) and 5 year revision rates (5.9 per 1000 
implant- years (95% CI 4.8 to 7.2) in April 2008 to 2.9 (95% 
CI 2.2 to 3.9) in December 2011). The positive trends in 
all outcomes started before ERAS was implemented and 
continued during and after the programme.
Conclusions Patient outcomes after hip replacement 
have improved over the last decade. A national ERAS 
programme maintained this improvement but did not alter 
the existing rate of change.
IntrODuCtIOn
Osteoarthritis represents a significant, and 
growing, population health burden world-
wide.1 In the UK, over 1 million adults 
aged over 45 years consult general practice 
for osteoarthritis each year.2 Osteoarthritis 
accounts for £3.2 billion in lost productivity 
in the UK,3 with total direct and indirect costs 
equivalent to 0.25% to 0.50% of the gross 
domestic product.4 5 Almost 88 000 primary 
hip replacement operations were undertaken 
during 2016 in the National Health Service 
(NHS), over 90% of which were for osteoar-
thritis. This number continues to increase.6
Between April 2009 and March 2011, the 
UK Department of Health implemented an 
Enhanced Recovery After Surgery (ERAS) 
Partnership Programme7 to improve recovery 
in major planned colorectal, musculoskeletal, 
gynaecological and urological surgical path-
ways. The first year of the programme focused 
on learning best practice from pioneer units 
of ERAS practice in the NHS. ERAS has a 
series of evidence- based care elements that 
all support recovery by reducing the bodily 
stress reactions caused by injury during 
surgery. These reductions in the stress 
responses are of particular importance for 
strengths and limitations of this study
 ► Our study design is a ‘natural experiment’ which 
controlled for unobservable sources of confounding. 
This approach for evaluating complex interventions 
allows for causal inferences without randomised 
controlled experiments.
 ► Routinely collected data provided actual- practice 
information on trends in length of stay, patient re-
ported outcome measures of hip pain and function, 
complications and revision surgeries following pri-
mary hip replacement procedures.
 ► A limitation is the variation in interpretation and 
adoption across centres because what constitutes 
Enhanced Recovery After Surgery (ERAS) was not 
clearly established after the expected identifica-
tion of best practices in the first year of the ERAS 
programme.
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the vulnerable patient with comorbidities, who is often 
also frail and elderly.8 It collected information about 
principles of enhanced recovery, clinical elements of 
the patient pathway, metrics and success factors. It estab-
lished a website to share information and resources, 
generated a financial and equality impact evaluation, 
published an implementation guide and developed 
an online reporting tool to support implementation. 
A lead for enhanced recovery was named in each local 
health authority to prepare for the spread of the ERAS 
programme across the NHS during the implementation 
phase in the programme’s second year.
The ERAS in musculoskeletal care focused on planned 
hip and knee replacement surgeries. ERAS is a complex 
intervention9 10 to improve several areas of care across 
a patient’s pathway through surgery. Preoperatively, 
ERAS aims for the patient to be in the best possible 
condition for surgery. In primary care haemoglobin 
levels and pre- existing comorbidities like diabetes are 
assessed. At the hospital nurses test cardiopulmonary 
exercise and appropriate anaesthetic for covering 
surgery is evaluated. In addition, there is informed 
decision- making after offering to the patient informa-
tion and managing her/his expectations. At the admis-
sion, hospitals arrange to admit patients the same day of 
surgery, fluid hydration is optimised using oral complex 
carbohydrates to reduce patient anxiety, reduce the 
body’s resistance to insulin and inflammatory response. 
Perioperatively, ERAS aims to give the patient the best 
possible management during and after surgery.11 It 
includes: minimally invasive surgery if possible, indi-
vidualised fluid therapy, avoid crystalloid overload, use 
of regional/spinal and local anaesthetic with sedation 
and hypothermia prevention. Postoperatively, ERAS 
aims to give the patient the best possible rehabilitation. 
It includes: no routine use of wound drains and/or 
nasogastric tubes, active, planned mobilisation within 
24 hours, early oral hydration and nutrition, intrave-
nous therapy stopped early, catheters removed early, 
oral analgesia avoiding systemic opiates where possible. 
Follow- up covers: discharge on planned day or when 
criteria met, therapy support (stoma, physiotherapy, 
dietitian…) and 24 hours telephone follow- up if appro-
priate. Patients are given information before and after 
surgery, such as changes to make around the home, 
strengthening exercises and changes to nutrition. ERAS 
aims to enable earlier return home from hospital with 
tailored discharge, when suitable for the patient.
Despite their widespread implementation, there 
is limited evidence about the effectiveness of ERAS 
programmes in hip and knee replacement surgery.12 
Length of hospital stay has been declining prior to the 
intervention, and we hypothesised that after the imple-
mentation of ERAS, this downward secular trend would 
decline faster. For the outcomes of complications, revi-
sion, pain and function, we did not have a specific a- prior 
hypothesis as it is unclear what impact ERAS would have 
on these outcomes. We aimed to determine whether 
implementing ERAS in hip replacement has led to 
improved patient outcomes and shorter hospital stays.
MethODs
Data source
We used data from the UK National Joint Registry (NJR), 
which contains data on hip replacement surgeries from 
all English and Welsh hospitals. It includes 2 million 
patients since 2003 and covers 95% and 91% of primary 
hip replacements and revisions, respectively.13
Data linkages
Primary operations were linked with Hospital Episode 
Statistics (HES) data, which contain records of all NHS 
funded inpatient episodes undertaken in NHS trusts in 
England (125 million each year). Planned hip replace-
ments were linked to patient reported outcome measures 
(PROMs). Patients funded by the NHS in England are 
asked to complete questionnaires before and 6 months 
after surgery to evaluate their perceived improvement 
in health. We retrieved a cohort of patients undergoing 
planned hip replacement in England between April 2008 
and December 2016. Mortality data were matched to the 
Office for National Statistics database.
Outcome measures
We evaluated trends in hospital stay length for patients 
undergoing primary hip replacement. Length of stay was 
calculated as the number of days between the hospital 
admission and discharge dates. We used the same set 
of patients to estimate the inpatient cost for the index 
episode using NHS reference costs from 2015/2016.14 
We estimated the mean cost per bed day based on each 
patient’s healthcare resource use and length of hospital 
stay. online supplementary appendix 1 further explains 
the cost methods.
We also assessed the absolute change in the Oxford Hip 
Score (OHS), a PROM. Patients complete the same ques-
tionnaire about their hip pain and function before and 6 
months after surgery.15 Each question is scored between 
0 (worst symptoms) and 4 (least symptoms). The scores 
from the 12 questions are summed to give a total score 
between 0 (worst) and 48 (best). We calculated the differ-
ence between the total scores 6 months post- surgery and 
at baseline to obtain a measure of change associated with 
surgery. Higher positive values for OHS change represent 
greater self- reported improvement in pain and function.
We calculated the 6 months post- surgery complication 
proportions. We defined postoperative complications 
as one or more events happening up to 6 months after 
primary hip replacement: stroke (excluding transient 
ischaemic attack), respiratory infection, acute myocar-
dial infarction, pulmonary embolism/deep vein throm-
bosis, urinary tract infection, wound disruption, surgical 
site infection, fracture after implant, complication of 
prosthesis, neurovascular injury, acute renal failure or 
blood transfusion. We identified these complications in 
copyright.
 o
n
 N
ovem
ber 29, 2019 at University of Keele. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-031599 on 21 November 2019. Downloaded from 
3Garriga C, et al. BMJ Open 2019;9:e031599. doi:10.1136/bmjopen-2019-031599
Open access
Figure 1 Flow diagram showing selection of patients for inclusion in this study (blue shows inclusion and orange shows 
exclusion).
HES data using diagnosis codes from the ‘International 
Statistical Classification of Diseases and Related Health 
Problems 10th Revision’ (ICD-10) (online supplementary 
appendix 2), except for blood transfusion, for which we 
used the ‘Classification of Interventions and Procedures 
version 4’ codes (online supplementary appendix 3).
We evaluated the rate of revision surgery up to 5 years 
after primary hip replacement. We included revisions 
declared to the NJR registry by surgeons16 and reported 
to HES using codes from online supplementary appendix 
4. We specified our analysis time in years, reporting the 
rate as the number of revisions per 1000 implant- years.
Intervention
The ERAS programme for hip replacement surgery was 
implemented nationally between April 2009 and March 
2011. During the first year the programme focused on 
identifying best practice, determining clinical elements 
of the patient pathway, publishing an implementation 
guide, supporting early adopters of the programme to 
better understand key factors for implementation and 
sustainability.17 During the second year ERAS supported 
local health areas for delivering and commissioning 
implementation of ERAS.
Potential modifiers
We evaluated whether trends in hospital stay length and 
OHS change after surgery differed by age at the time of 
primary hip replacement (18 to 59, 60 to 69, 70 to 79, 80 to 
84 or ≥85 years) and presence of comorbidities according 
to the Charlson classification18 (no comorbidities vs one 
or more comorbidities): myocardial infarction, conges-
tive heart failure, peripheral vascular disease, cerebrovas-
cular disease, dementia, chronic obstructive pulmonary 
disease, connective tissue disease, peptic ulcer disease, 
mild liver disease, mild diabetes, hemiplegia, moderate/
severe renal disease, severe diabetes (ie, with organ 
damage), tumour, leukaemia, lymphoma, moderate/
severe liver disease, AIDS and metastatic solid tumour. 
The ICD-10 codes used are listed in online supplemen-
tary appendix 5.
Participants and inclusion criteria
We included patients receiving planned hip replacement 
surgery (figure 1) between 1 April 2008 and 31 December 
2016. We excluded patients without a concordant date of 
replacement between NJR and HES registries.
When analysing length of stay, we also excluded patients 
staying more than 15 days in hospital and patients with a 
missing hospital stay length or a hospital discharge date 
before their hospital admission date. When analysing 
change in OHS, we also excluded patients missing baseline 
and/or 6 month follow- up OHS scores. When analysing 
complications, we also excluded patients with compli-
cations before the surgery date and those with surgery 
after June 2016 to guarantee all patients had at least 6 
months of follow- up. When analysing 5 year revision rates, 
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we excluded patients who received surgery after 2011 to 
ensure all patients had at least 5 years of follow- up.
Missing data
We excluded patients with missing length of hospital stay 
or missing OHS data from the respective analyses. We 
used Pearson’s χ2 statistic to compare missingness in the 
OHS measure before, during and after ERAS implemen-
tation (April 2008 to March 2009, April 2009 to March 
2011 and April 2011 to December 2016), across patient 
age (18 to 59, 60 to 69, 70 to 79, 80 to 84 and ≥85 years) 
and in the presence and absence of comorbidities. We 
also compared the distribution of patients with and 
without OHS data by study period, patient age and pres-
ence of comorbidities.
study design and statistical analysis
We used a natural experimental study design.19 We evalu-
ated the effect of ERAS on trends before, during and after 
its implementation.20 21 Trusts could choose when to start 
implementing the programme within the implementa-
tion period (April 2009 to March 2011), and we assumed 
that they only implemented the programme within this 
period. We described the trends by calculating monthly 
outcomes as means (length of stay, bed costs, change in 
OHS), proportions (complications) or rates (revision), 
and their 95% CIs. We estimated a fractional polynomial 
over the study period and plotted the resulting curve with 
the CI of the mean.
We used an interrupted time series approach to esti-
mate changes in outcomes during and immediately after 
the intervention period, while controlling for baseline 
levels and trends. We modelled aggregated data points 
of each outcome of interest by month using segmented 
linear regression21:
Yt = β0 + (β1 * time t) + (β2 * ERAS0) + (β3 * time after 
ERAS0) + (β4 * ERAS end) + (β5 * time after ERAS end)+et.
Yt is the mean of each outcome for patients undergoing 
primary hip replacements – mean days in hospital for 
length of stay, mean OHS change for the PROM analysis, 
mean proportion of complications for 6 month complica-
tions outcome and mean rate of revisions of primary hip 
replacements for the 5 year revision outcome – in month t. 
‘Time’ is a continuous variable representing the number 
of months from the start of the observation period (April 
2008) until time t. β0 estimates the baseline level of the 
outcome at the beginning of the time series (April 2008). 
β1 estimates the trend before ERAS was implemented in 
April 2009. β2 is the change in level immediately after 
the intervention (ERAS0 = April 2009). β3 estimates the 
change in the trend in the monthly mean (number or 
rate, depending on outcome) after ERAS started (ie, 
ERAS implementation trend). β4 is the change in level 
immediately after the end of the intervention (ERAS end = 
March 2011). β5 estimates the change in the trend in the 
mean monthly number or rate (depending on outcome) 
after ERAS ended.
We excluded non- significant terms using a backward 
approach to maximise statistical power, producing a 
parsimonious model with meaningful selected variables. 
In preliminary analysis we checked for autocorrelation 
with the previous month, 2 months…12 months using 
Durbin’s alternative test.22 As autocorrelation invalidated 
the interpretation of the model, we estimated the linear 
regression models with Newey- West standard errors.23 
Parsimonious models were generated using the variables 
previously selected in the backward regression. We also 
report the full models.
All analyses were conducted using Stata V.13.1 statistical 
software (StataCorp, College Station, Texas). We followed 
the STROBE (Strengthening the Reporting of Observa-
tional Studies in Epidemiology) guideline in reporting 
this study.24
Patient and public involvement
The James Lind Alliance has identified the need for 
involving patients in identifying outcomes that matter to 
them (patient- identified outcomes). The study has been 
developed in collaboration with the University of Bristol, 
Musculoskeletal Research Unit’s Patient Experience Part-
nership in Research (PEP- R) group to identify outcomes 
from those available in the routine data sets available for 
this study. The top outcomes were: (1) pain and func-
tion, (2) complications (particularly hospital- acquired 
infection), (3) length of stay (dependent on the level of 
support at home), (4) revision surgery and (5) mortality 
(rated low importance) (further detail is provided in 
online supplementary text S1).
results
We identified 438 921 planned primary hip replacements 
between April 2008 and December 2016 (figure 1). Sixty 
per cent of patients were women and the average age 
was 69 years (SD ±11 years). The mean body mass index 
(BMI) at primary surgery of 28.9 kg/m2 (SD ±5.2 kg/m2) 
fell into the overweight category,25 although BMI was 
missing for 28% of patients. Most patients (84%) had a 
physical status26 of ‘mild’ or ‘fit’.
length of stay
Hospital stays shortened from 5.6 days (95% CI 5.5 to 
5.7) in April 2008 to 3.6 (95% CI 3.6 to 3.7) in December 
2016 (figure 2A). As shown in table 1, they were already 
shortening significantly by −0.020% every month (95% CI 
−0.023% to −0.017%) before ERAS (full models in online 
supplementary table 1S1). Hospital stay shortened more 
quickly (−0.033%) during the implementation period 
(April 2009 to March 2011), then declined at a slower rate 
(−0.002%) once ERAS ended (April 2011 to December 
2016).
Although older patients had longer hospital stays, all age 
groups shared the shortening stay trend (figure 3, online 
supplementary tables S2,S3). For example, those aged 18 
to 59 years decreased from 4.7 days (95% CI 4.6 to 4.9) in 
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Figure 2 Effect of the enhanced recovery after surgery (ERAS) programme implemented from April 2009 to March 2011 on 
trends in outcomes following primary hip replacement in England, UK, 2008 to 2016, by month. (A) length of hospital stay, (B) 
change in self- reported pain and function, measured using the Oxford Hip Score (OHS) at baseline and 6 months after the 
surgery, (C) any complication in the 6 months after surgery and (D) hip revision in the 5 years after surgery.
April 2008 to 3.0 days (95% CI 2.9 to 3.1) in December 2016 
and those aged ≥85 years decreased from 8.1 days (95% CI 
7.7 to 8.6) in April 2008 to 5.3 days (95% CI 4.9 to 5.6) in 
December 2016. Patients with and without pre- existing 
comorbidity also had shortening hospital stays (figure 4).
We estimated cost data for 432 143 patients. The mean 
inpatient bed day cost over time showed a similar trend to 
that observed for hospital stay length. The overall mean 
cost of the index hospital episode decreased from £7573 
(95% CI £7477 to £7668) in April 2008 to £5239 (95% CI 
£5171 to £5306) in December 2016 (online supplementary 
figure S1).
Ohs change
We excluded 48% of patients with missing OHS informa-
tion from the change in OHS analysis (figure 1). We found 
more missing OHS data before the intervention (89.7%) 
than during (41.9%) or after (45.0%) the intervention 
(online supplementary table S4). online supplementary 
table S5 shows more patients without OHS change data 
than with this data in the period prior to ERAS (16.2% and 
1.7%, respectively).
Self- reported OHS scores improved over the study 
period, with an increase in OHS 6 months after surgery 
of 17.7 points (95% CI 16.4 to 19.0) in April 2008, to 
22.9 points (95% CI 21.8 to 23.9) in December 2016 
(figure 2B). This trend was also seen in patients with and 
without comorbidities and in all age groups, except in 
those aged ≥85 years, whose change in OHS remained 
stable over the study period (online supplementary 
figures S2,S3, online supplementary tables S6,S7).
According to the interrupted time series model 
(table 1), OHS change increased significantly by 0.158% 
(95% CI 0.130% to 0.186%) every month before the 
intervention (see online supplementary table S1 for the 
full model). During ERAS implementation (April 2009 
to March 2011), the increase continued but slowed to 
0.027%. Change in OHS then became stable after ERAS 
implementation ended (April 2011 to December 2016).
Complications at 6 months
Six thousand two hundred and thirty- two (1.6%) patients 
with a primary hip replacement between April 2008 
and March 2016 had one or more complication in the 
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Table 1 Temporal trends in patients undergoing planned primary hip replacement from April 2008 to December 2016, 
parsimonious models with Newey- West standard errors
Parameter Coefficient Lower 95% CI Upper 95% CI P value
Length of stay in hospital
  Intercept 5.674 5.655 5.693 <0.001
  Monthly trend −0.020 −0.023 −0.017 <0.001
  Level change ERAS0 0.176 0.120 0.232 <0.001
  Trend change after ERAS0 −0.013 −0.017 −0.009 <0.001
  Level change ERASend −0.102 −0.203 −0.001 0.049
  Trend change after ERASend 0.019 0.015 0.022 <0.001
Change in Oxford hip score (score at 6 months – score at baseline)
  Intercept 17.063 16.896 17.230 <0.001
  Monthly trend 0.158 0.130 0.186 <0.001
  Level change ERAS0 0.772 0.538 1.006 <0.001
  Trend change after ERAS0 −0.131 −0.161 −0.101 <0.001
  Level change ERASend 0.564 0.208 0.920 0.002
  Trend change after ERASend −0.013 −0.025 −0.001 0.039
Complication by 6 months after surgery
  Intercept 4.044 3.465 4.624 <0.001
  Monthly trend −0.078 −0.096 −0.061 <0.001
  Level change ERAS0 ─ ─ ─ ─
  Trend change after ERAS0 ─ ─ ─ ─
  Level change ERASend ─ ─ ─ ─
  Trend change after ERASend 0.078 0.056 0.100 <0.001
Revision rates by 5 years after surgery
  Intercept 7.901 7.653 8.149 <0.001
  Monthly trend −0.098 −0.108 −0.087 <0.001
  Level change ERAS0 ─ ─ ─ ─
  Trend change after ERAS0 ─ ─ ─ ─
  Level change ERASend ─ ─ ─ ─
  Trend change after ERASend 0.091 0.052 0.129 <0.001
Confidence intervals, CI; Enhanced Recovery After Surgery, ERAS; start point of ERAS intervention in April 2009, ERAS0; end point of ERAS 
intervention in March 2011, ERASend; ─, p≥0.05.
6 months after surgery. The proportion of complica-
tions at 6 months decreased from 4.1% (95% CI 3.4 to 
4.7) to 1.7% (95% CI 1.3 to 2.1) over the study period 
(figure 2C). According to the interrupted time series 
model, complications at 6 months decreased by −0.078% 
(95% CI −0.096% to −0.071%) every month before the 
intervention (table 1). During the intervention, the trend 
reversed and complications increased by 0.078%. The 
proportion of complications stabilised after the interven-
tion ended.
Five year revision rates
According to the NJR registry, 3392 (2.1%) patients 
with a primary hip replacement between April 2008 
and December 2011 had a hip revision in the following 
5 years. We found 840 more 5 year revisions using HES, 
giving a total of 4232 (2.6%). Rates of 5 year hip revision 
decreased from 7.6 per 1000 implant- years (95% CI 6.4 
to 9.2) at risk in April 2008 to 3.8 (95% CI 3.0 to 4.9) in 
December 2011 (figure 2D).
According to a parsimonious model of 5 year hip revi-
sion rates (table 1), there was a significant downward 
trend of −0.098 per 1000 implant- years (95% CI −0.108 
to −0.087) before the implementation of the intervention 
(April 2009 to March 2011) (see online supplementary 
table S1 for the full model). The trend reversed after the 
intervention ended (April 2011 to December 2016) to 
increase 0.091 per 1000 implant- years (95% CI 0.052 to 
0.129).
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Figure 3 Trends in length of hospital stay following primary hip replacement according to patient age categories in England, 
UK, 2008 to 2016, by month. Enhanced recovery after surgery (ERAS) programme implemented in England from April 2009 to 
March 2011.
DIsCussIOn
We have shown that primary hip replacement outcomes 
have been improving since 2008, with decreasing length 
of hospital stay, estimated average inpatient bed day costs, 
complications and 5 year revision risk, and improving 
patient- reported pain and function. These positive trends 
were seen across all age groups and in those with and 
without comorbidity, and began before the NHS ERAS 
programme was implemented. Hospital stays have short-
ened without adversely affecting patient outcomes.
We hypothesised that the national ERAS intervention 
would improve primary hip replacement outcomes by 
changing trends during and after its implementation. 
Our hypothesis was not confirmed, as ERAS did not influ-
ence existing trends. However, we collected only 1 year 
of data before the intervention was implemented (April 
2008 to March 2009), in comparison with 2 years of data 
during implementation (April 2009 to March 2011) and 
5 years of data post- intervention (April 2011 to December 
2016). We know from other UK studies that length of stay 
has been in gradual decline in the years prior to 2008, 
where Burn et al found that in 1997 mean hospital stays 
for total hip replacement was 14.28 days, and in 2008, 
before the ERAS intervention, 7.94 days27.
Although our study design controlled for unobserv-
able sources of confounding, we stratified by age and 
presence/absence of comorbidities at surgery to detect 
patterns in outcome variation. This approach for evalu-
ating complex interventions allows for strong causal infer-
ences without randomised controlled experiments.10 20
For this ‘natural experiment’, we assumed that ERAS 
was implemented homogenously across all England NHS 
trusts in the 2 year implementation period. This assump-
tion is unlikely to be true. The shortening hospital stays 
and improved outcomes seen before April 2009 may 
reflect some trusts implementing ERAS elements before 
the national programme began. Shortening hospital stays 
before ERAS may also reflect attempts to improve the 
cost- effectiveness of hip replacement surgery, which is an 
important expenditure for the NHS.27–29
The hospitals implemented ERAS on different dates, 
and some had not implemented ERAS by March 2011.17 
The Department of Health surveyed trusts on their use 
of ERAS near the end of the implementation period 
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Figure 4 Trends in length of hospital stay following primary hip replacement according to whether patients do or do not 
present with comorbidities, in England, UK, 2008 to 2016, by month. Enhanced recovery after surgery (ERAS) programme 
implemented in England from April 2009 to March 2011.
(February 2011) and reported full implementation by 
81 consultant teams, partial implementation by about 20 
teams and plans to implement ERAS by about 30 teams. 
As the Department of Health did not clearly describe 
ERAS after best practices were identified in the first 
year of the programme,30 there is also variation in the 
teams’ interpretation and adoption of the programme. 
The Department of Health guideline did not indicate 
how long ERAS should be implemented for and its later 
report did not measure actual implementation periods 
in each hospital.17 30 Considering the complexity of the 
intervention and stakeholders involved, implementa-
tion length is likely to have varied between hospitals. 
Our quasi- experimental approach smooths the potential 
dissimilarities.
Existing systematic reviews and randomised clinical 
trials have found that ERAS programmes for planned 
colorectal, joint replacement and other surgeries reduced 
hospital stays when compared with conventional care.12 
Many kinds of ERAS programmes for hip replacement 
have been investigated: physical therapy the same day of 
the surgery in the recovery room31; preoperative patient 
education, postoperative multimodal analgesia with 
periarticular injections, early physiotherapy and reha-
bilitation and discharge home with an outpatient reha-
bilitation programme32 33; patient and staff education 
on ‘enhanced recovery’ principles, preadmission medi-
cation, perioperative urinary catheterisation, low- dose 
spinal anaesthesia and aiming for same- day mobilisation34; 
perioperative information, pain relief, nausea control, 
nutrition, mobilisation and elimination35; preoperative 
patient seminar, treatment of pain (spinal anaesthesia) 
and early mobilisation, standardised programme in the 
operating theatre (tranexamic acid and no drains), 1 to 
2 hours of a multimodal fast- track rehabilitation regime, 
daily physiotherapy within the first 24 hours and a multi-
modal oral opioid- sparing analgesia36; or a periopera-
tive analgesic blocking the peripheral nerve.37 However, 
these studies involved small sample sizes (170, 57, 1256, 
630, 28, 98, 15),31–37 were limited to one hospital or trust 
and only compared their intervention with traditional 
management. They cannot be generalised to the wider 
population. We investigated whether the ERAS for hip 
replacement was successfully implemented by comparing 
with a pre- ERAS period, as was done in other studies,32–34 
but for the first time, by also comparing with the post- 
intervention period. We also included all of the hospitals 
in one country.
Shorter hospital stays were reflected in lower estimated 
average inpatient bed day costs. Most surgery episodes 
in the data set had a hospital stay shorter than the trim 
point for the cost of the relevant healthcare resource 
use group. A drop in hospital stay length within the trim 
point would not be reflected by a change in the estimated 
average episode costs, if we assign the same unit cost to all 
patients in the same healthcare resource use group who 
had a length of stay shorter than the trim point. We there-
fore estimated the true reduction in NHS expenditure 
by estimating a cost per bed day reflecting each patient’s 
hospital stay length.
OHS change scores increased across the study period: 
the difference between pain and function at baseline 
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and 6 months post- surgery was greater at the end of 2016 
than in 2008, indicating less pain and better function 
after surgery. A review of ERAS in total hip replacement 
showed that better improvement in pain and function 
scores could be related to making patients active partic-
ipants in their recovery and managing patient expecta-
tions.29 A Cochrane review on preoperative education for 
hip or knee replacement do not find benefits over usual 
care, but did find a non- significant reduction in pain and 
better function associated with perioperative education.38
Complications 6 months after surgery were decreasing 
before ERAS was implemented, remained steady during 
the ERAS period and increased after the intervention 
ended. Discharging patients too soon after surgery 
could increase complications. A meta- analysis of ERAS 
programmes for colorectal surgery did not find evidence 
of increased surgical site infections or anastomotic 
leakage, classified as surgical complications (relative 
risk=0.76, 95 % CI 0.54 to 1.08), and found that cardiovas-
cular, pulmonary and infectious medical complications 
decreased (relative risk=0.40, 95 % CI 0.27 to 0.61).39 
Patients with diabetes undergoing hip and knee replace-
ment under ERAS protocols had a lower additional risk 
for complications otherwise associated with operating on 
patients with diabetes.40
The 5 year revision surgery rates dropped over the study 
period, a desirable finding as the revision procedure is 
more complicated than the initial procedure.41 Revision 
rates may have declined due to the UK National Institute 
for Health and Care Excellence recommendation to only 
use implants with a 10 year revision rate of 5% or lower, to 
avoid low- quality prostheses.28
The promising improvements in primary hip replace-
ment outcomes reported here were achieved amidst 
increasingly strained NHS funding and hospital budgets. 
NHS funding growth in our study period was slower than 
historical trends.42 There are fewer hospital beds avail-
able for hip replacement today than at the beginning 
of the study period, and wards have been closed. For 
example, there was an average daily 10 015 occupied beds 
open overnight for trauma and orthopaedics in England 
between April 2010 and June 2010, dropping to 8770 
between October 2016 and December 2016.43 Conversely, 
the number of primary hip replacements in England 
increased from 67 128 in 2008 to 87 733 in 2016.6 It has 
been estimated that 97 516 total hip replacements will 
take place in 2035.44 Meeting this demand with existing 
or lower capacity will require efficiencies. During the 
period of our study we observed an increasing trend in 
the proportion of NHS funded primary hip replacements 
being carried out in independent hospitals (increasing 
from around 10% in 2008 to 27% in 2016) and a small 
increase in those within Independent Sector Treatment 
Centres (from 3.5% in 2008 to 5% in 2016). These 
changes will have supported an increase in capacity for 
surgery (although such centres typically treat healthier 
and less complex patients than nearby public hospi-
tals, with a worsening case- mix of those patients treated 
in public hospitals).45 Such changes in the sorting of 
routine and complex patients between public and private 
hospital settings over time could also influence observed 
changes in outcomes of surgery over time. ERAS has 
kept the improvements happening when other changes 
were occurring which may have caused deterioration, for 
example, older, sicker and more obese patients. However, 
changes in the case- mix of patients have not altered 
improving trends in outcomes of surgery.
An important issue is the high variation in services and 
practices across English hospitals. The Getting It Right 
First Time (GIRFT) programme aims to reduce discrep-
ancies in activity volume, implant choice and guideline 
follow- up between hospitals.46 Despite national improve-
ments in hip replacement outcomes, GIRFT reports 
substantial variation in outcomes between hospital trusts. 
In 2016, the mean length of hospital stay after primary hip 
replacement varied between 2.5 and 11.6 days, and OHS 
change varied between 12.0 and 23.5 points. Although 
the national picture has improved for patients, there is 
still work remaining to understand and reduce unwar-
ranted outcome variations between individual hospitals. 
This study would be strengthened with the comparison 
with trends from another country (Wales for example). 
However, we do not have access to hospital admission 
data for Wales for this study. In addition, the comparison 
with another procedure where the enhanced recovery 
intervention was not applied, could also act as a poten-
tial control group (such as cataract surgery). Neverthe-
less, the importance of an external control group would 
have been higher if within this study we had observed a 
significant impact of ERAS intervention on a change in 
trend in outcomes of surgery, as it would have given reas-
surance of an intervention effect was not observed in the 
control group. However, in the case of our study, we do 
not observe an intervention effect — rather than contin-
uation of an existing secular trend that was happening 
before introduction of the intervention.
Although the NJR registry captures all primary hip 
replacements including those undertaken in the private 
sector linkage to English HES data means that we only 
have access to information on patients receiving NHS 
funded operations including public and private hospi-
tals. Therefore, this study do not include private funded 
operations undertaken by the independent sector. It is 
estimated 13.7% to 19.7% of all hip replacements were 
carried by the independent sector in 2012 to 2013 and 
2016 to 2017, respectively (Source: Hospital Episode 
Statistics, NHS Digital.)
COnClusIOn
Our study shows that outcomes after planned hip replace-
ment are better today than 10 years ago. Hospital stays 
shortened substantially from 2008 to 2016 for all age 
groups and in people with and without comorbidity, 
without adversely affecting patient outcomes. Patient- 
reported pain and function have improved, revision rates 
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are in decline and complication rates remain stable. The 
introduction of a national ERAS programme maintained 
this improvement but did not alter the rate of change 
already underway.
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